Overview

Antibody Empire opens the BioLionaire Scientist series with a deep exploration of how monoclonal antibodies evolved from academic immunology experiments into one of the most powerful therapeutic platforms in modern medicine. This volume examines the scientific breakthroughs, engineering refinements, clinical turning points, and strategic decisions that transformed antibodies into a multi-hundred-billion-dollar global industry. Rather than presenting a simplified success narrative, the book analyzes the real mechanisms behind platform creation - from hybridoma technology and recombinant engineering to immune checkpoint modulation and translational funding pathways. Through detailed scientific discussion and strategic analysis, the book demonstrates how curiosity-driven laboratory discoveries matured into dominant oncology and autoimmune therapeutics. It connects molecular immunology to manufacturing scale, patent protection, regulatory positioning, and capital formation. This is a scientifically rigorous guide for researchers who want to understand not only how antibodies work - but how therapeutic empires are built. Who This Book Is ForThis volume is written for graduate students, postdoctoral researchers, clinician-scientists, biotechnology founders, translational investigators, and professionals seeking a deeper understanding of biologics strategy. It is equally suited for academic libraries, research institutions, and innovation-focused biotech teams. What This Book CoversThe book explores the biological foundations of antibody specificity, immune recognition, and monoclonal antibody development. It then moves into the engineering era - including humanization, Fc optimization, bispecific formats, and antibody-drug conjugates. Major oncology case studies such as CD20 targeting, HER2-directed therapy, CTLA-4 blockade, and PD-1 immune checkpoint modulation are analyzed not only for their biological significance, but for their strategic and commercial implications. Later chapters address manufacturing scalability, quality control systems, patent architecture, translational grant funding, SBIR mechanisms, startup formation, and biotech valuation frameworks. The volume closes by synthesizing scientific innovation with execution strategy - outlining the BioLionaire blueprint for platform dominance. Table of ContentsPart I - The Science of Antibodies Chapter 1 - Antibody Basics Chapter 2 - Monoclonal Antibodies Chapter 3 - Engineering the Future Part II - From Bench to Blockbuster Chapter 4 - The First Billion-Dollar Antibodies Chapter 5 - The Immuno-Oncology Era Chapter 6 - Antibodies Beyond Cancer Part III - The Business of Antibodies Chapter 7 - Anatomy of a Blockbuster Deal Chapter 8 - The Biotech Playbook Chapter 9 - Manufacturing and the Money Pipeline Part IV - Future Antibody Empire Chapter 10 - Next-Gen Antibodies Chapter 11 - Deep learning for antibody design Chapter 12 - Building Your Own Antibody Path Chapter 13 - Approaching Funding Bodies Appendices Appendix A - Antibodies Discussed in Antibody Empire Appendix B - Sample K99/R00 NIH Proposal Appendix C - Common Antibody CROs Appendix D - How to Choose a CRO Glossary Index Companies & Platforms Discussed in this Volume Essential Reading

Full Product Details

9798274457866

Table of Contents

Reviews

Author Information

Tab Content 6

Countries Available